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Abstract Anxiety and fear are often associated with
chronic conditions such as cancer. This paper targets the
cost-effectiveness analysis of a cognitive-behavioral group
therapy (CBT) in comparison to a client-centered, sup-
portive-experiential group therapy (SET) in cancer patients
with dysfunctional fear of progression. An incremental
cost-effectiveness analysis was performed using data from
a randomized controlled trial among cancer patients
receiving inpatient rehabilitation. The means, 95% confi-
dence intervals [95% CI], incremental cost-effectiveness
graphic and acceptability curve were obtained from 1,000
bootstrap replications. A total of 174 patients were inclu-
ded in the economic evaluation. The estimated means [95%
CI] of direct costs and reduction of fear of progression
were €9,045.03 [6,359.07; 12,091.87] and 1.41 [0.93; 1.92]
for patients in the SET and €6,682.78 [4,998.09; 8,440.95]
and 1.44 [1.02; 1.09] for patients in the CBT. The
incremental cost-effectiveness ratio [95% CI] amounts to
minus €78,741.66 [-154,987.20; 110,486.32] for an addi-
tional unit of effect. Given the acceptability curve, there is
a 92.4% chance that the CBT, compared with the SET, is
cost-effective without the need of additional costs to pay-
ers. Our main result is the superior cost-effectiveness of the
cognitive-behavioral intervention program in comparison
to the non-directive encounter group for our sample of
cancer patients with high levels of anxiety.
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Introduction
Anxiety and fear are often associated with conditions such
as cancer. In addition to the burden to patients and their
families, fear and anxiety associated with medical condi-
tions have important socio-economic consequences, such
as high health care use costs [1–3]. Therefore, interven-
tions, which can reduce fear and anxiety of patients suf-
fering from chronic conditions, would not only benefit
patients directly, but could also contribute to the reduction
of the economic burden to society.
An important aspect of fear, especially in chronic pro-
gressive diseases such as cancer, is the fear of progression
or, more specifically, fear on the part of patients that their
disease will progress and lead to either death or disability
[4]. Fear of progression may be ameliorated with cognitive-
behavioral therapies (CBT). However, it is still unclear
whether or not and to what extent CBT can reduce fear and
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anxiety, in general, and fear of progression, in particular
[5–8]. Nevertheless, a recent study by Herschbach found a
statistically significant long-term reduction of fear of pro-
gression in cancer patients after CBT as well as after a
client-centered, supportive-experiential group therapy
(SET) [9, 10].
While the demonstration of reduced fear of progression
is an important patient-relevant outcome, it would be as
important from a societal perspective to demonstrate
whether CBT and SET can result in the reduction of direct
and indirect medical costs. More specifically, whether CBT
can be more cost-effective than SET needs to be studied.
Cost reduction was addressed and demonstrated in studies
among cancer patients [11, 12]. However, assessment of
outcomes in psychosocial interventions applied to cancer
populations has been heavily weighted in domains such as
quality of life and psychological distress, whereas eco-
nomic evaluations are altogether lacking [8].
The objective of our study was therefore to perform an
incremental cost-effectiveness analysis of a randomized
controlled trial published by Herschbach et al. [10]
comparing a cognitive-behavioral group therapy (CBT)
focusing on fear of progression to client-centered,
supportive-experiential group therapy (SET).
Materials and methods
Study design
We performed an economic evaluation alongside a ran-
domized controlled trial. Participants were recruited
between November 2002 and December 2003 in two
rehabilitation clinics in the region of Bavaria, Germany.
Inclusion criteria were: breast, colon or cervical carcinoma
(at all illness phases), minimum age of 18 years, inpatient
rehabilitation and increased fear of progression measured
with the standardized Fear of Progression Questionnaire
[13]. Patients were excluded if they had cognitive impair-
ment, were bedridden or had poor command of the German
language. All patients had medical care insurance. A total
of 174 cancer patients were randomized into two inter-
vention groups (CBT or SET). Patients were assessed at
baseline, post-intervention and at the 3- and 12-month
follow-up after discharge.
Interventions
All patients underwent the same 3-week inpatient rehabil-
itation program. In addition to the standard rehabilitation
program, patients in both CBT and SET groups received
four sessions of group psychotherapy, each lasting 90 min.
While the CBT was a directive and specific intervention
aimed at confronting patients with their fears and making
them learn to cope with them, the SET was a non-directive
and unspecific intervention focusing on emotional expres-
sion, mutual support and reassurance, and social compari-
son [14].
Health-care utilization and costs
The economic evaluation was performed from the societal
perspective. As this study was conducted over a 1-year
period, costs and effects were left undiscounted. Incre-
mental intervention costs were calculated based on the
duration of the four sessions of group psychotherapy, group
size and salaries of the psychologists. Following the
Guidelines of the Working Group Methods in Health
Economic Evaluation (AG MEA), a 20% charge was added
to the calculated costs because of the time spent learning
the manuals, preparing the sessions and conducting
supervisions.
Patients of SET and CBT completed a retrospective
health-care resource use assessment questionnaire at
baseline and 12 months after rehabilitation. The question-
naire was developed following the guidelines proposed by
the Working Group Methods in Health Economic Evalua-
tion (AG MEA) [15]. We combined resource use volumes
with unit costs to obtain a net cost per patient. If resource
use was obtained for recall periods shorter than 12 months,
resource use data were extrapolated to obtain annual fig-
ures. Direct medical costs included visits to practitioners,
non-physician service utilization, inpatient and outpatient
hospital treatments, day care, medication, devices and aids.
Direct non-medical costs included loss of leisure time of
patients due to participation in self-help groups and of
parents or friends due to voluntary caregiving. Indirect
costs were assessed using the human capital approach and
calculated based on sick leave days. All costs were cal-
culated in euros.
Unit costs
All costs were calculated for the year 2004. Medication was
valuated on the basis of prices of the online German drugs
index book [16]. Devices and aids were valuated with
prices charged by the health-care funds of the regional
association of the AOK Bavaria [17]. Costs for the day-care
treatment were valuated in a conservative way with prices
charged in 2004 at the University of Munich Hospital. All
other index costs were proposed by the Working Group
Methods in Health Economic Evaluation (AG MEA) [18].
These index costs were extrapolated for 2004 using a factor
of 0.025 for the first year and 0.020 for the following years
based on recommendations of the AG MEA. An overview
of used costs is summarized in Table 1.
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Effectiveness data
We report means and standard deviations of the fear of
progression score and of the mental scale of the SF12
estimated in the original RCT.
Cost-effectiveness analysis
We performed an incremental cost-effectiveness analysis
(CEA) comparing both intervention groups (CBT and SET)
and calculated the incremental cost-effectiveness ratio
(ICER). Costs used in the CEA were the mean direct costs
(medical and non-medical) within the first year after dis-
charge. Effectiveness was measured with the standardized
Fear of Progression Questionnaire [4]. The mean fear of
progression at the 12-month follow-up minus the mean fear
of progression at baseline was used as an effectiveness
measure. As a reduction in the fear of progression is aimed,
effectiveness is expected to have negative figures. How-
ever, negative effectiveness measures in CEA are inter-
preted as being less effective. Owing to this fact, we
multiplied the effectiveness by negative 1 to get positive
figures in the event of more effects. To increase the com-
parability of this study to literature, we also performed the
incremental CEA considering as an effect the mental score
(MCS) of the 12-item Health Survey (SF-12) questionnaire
at the 12-month follow-up [19]. The SF-12 includes 12
items that are summarized in two weighted summary
scales: mental health (MCS) and physical health (PCS);
lower scores indicate more severe disability. The items
related to mental health (MCS) cover limitations to usual
activities and emotional state. The mental score of the
Table 1 Prices applied in the economic evaluation
Cost categories Price (€) Cost categories Price (€)
Physician visitsa Day-care treatment
General practitioner 16.03 Internal medicine 252.00
Neurologist 23.02 Surgical 484.00
Internist 34.62 Gynecology 175.00
Oncologist 21.89 Neurology 269.00
Radiology 235.00
Physical medicine 270.00
Oncology 575.00
Pain unit 285.00
Inpatient treatmentc Outpatient treatment (hospital)
Internal medicine 310.62 Gastroenterology 23.02
Surgical 349.55 Gynecology 26.88
Gynecology 377.33 Surgical 22.94
Gastroenterology 358.45 Urology 28.88
Urology 374.03 Dermatology 15.63
Dermatology 332.87 Internal medicine 34.62
Neurology 357.34 Orthopedic 23.43
Orthopedic 275.02 Cardiology 61.79
Cardiology 348.44 Radiology 83.54
Radiology 416.30 Pneumology 37.82
Rehabilitation oncology 105.00 Rheumatology 30.18
Rehabilitation orthopedics 102.00 Psychology 47.51
Mean value 390.00 Mean value 23.02
Psychotherapyd 47.51 Self-help groups (patient hour price) 17.80
Physiotherapy 21.89 Time of relatives (hour price) 17.80
Massage 9.70 Sick leave dayse 89.00
Ergotherapy 29.00 Psychologist minutesb 0.4910
a Price per visit
b Salary of rehabilitation clinic staff
c Price per day
d Price per session
e Price of a calendar day
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SF12 was chosen for comparison because of its close
association with the Fear of Progression Questionnaire [4].
Statistical analysis
We used non-parametric bootstrap techniques with 1,000
replications to estimate mean values and 95% confidence
intervals. To compare the means of the groups, we calcu-
lated the achieved significance level (ASL) using
bootstrap-t methods. The achieved significance level cor-
responds to the p value of a t test and will be called pboot
here [20]. A probability p value of\0.004 with Bonferroni
correction was considered significant. The uncertainty
surrounding the estimates of cost-effectiveness was illus-
trated by a cost-effectiveness acceptability curve. Mean
costs and mean effects distributions obtained from 1,000
bootstrap replications were used to plot the incremental
cost-effectiveness plane and the acceptability curve. As the
distribution of bootstrap estimates of costs and effects was
symmetric, we used the percentile method to estimate
confidence intervals [21].
Uncertainty in the cost and effectiveness estimates can
be allowed for by sensitivity analysis, statistical inference
or a combination of the two approaches [22]. We addressed
the uncertainty-presenting confidence intervals obtained
from bootstrap samples and calculated acceptability curves
for the incremental cost-effectiveness ratios [23]. Statistical
calculations were performed using SPSS version 14.0.
Results
Study population
Health-care resource data were collected for the 174 patients
randomized either in the CBT (N = 91) or in the SET
(N = 83) group. Baseline characteristics of the study pop-
ulation are reported in Table 2. The main diagnoses of the
study population in the CBT and SET groups, respectively,
were: 61.8 and 59% breast cancer, 6.7 and 8.4% colorectal
cancer, 9.0 and 8.4% bladder/prostate cancer, 12.4 and 8.4%
gynecological cancer and 10.1 and 15.7% other cancers.
Complete indirect cost data of patients employed at baseline
were available at the 12-month follow-up for 73 patients (44
CBT; 29 SET). No missing data were imputed.
Dropouts
By the 12-month follow-up, 37 patients (18 CBT; 19 SET)
had dropped out. Dropouts were very similar to participants
with regard to age, sex, employment and oncological
treatment in the past year. However, whereas at baseline
only 56.8% of dropouts were asymptomatic and 29.7% had
relapse or metastasis, 72.3% of the participants were
asymptomatic and only 14.6% had relapse or metastasis.
Ten dropouts died within the follow-up.
The baseline direct medical costs and indirect costs of
the dropouts were compared with those of the participants.
In comparison to participants [€14,321.19 (95% CI
12,217.62; 16,424.76)], dropouts incurred significantly
fewer direct medical costs at baseline [€8,875.66 (95% CI
6,171.16; 11,580.15)]. Dropouts incurred considerably
fewer costs in day-care treatment, inpatient treatment, non-
medical services, medication and ambulant physician
treatment than participants (data not shown). Although the
proportion of employed patients was very similar in both
groups, dropouts on average incurred fewer indirect costs
[6,366.92€ (95% CI 2,501.48; 10,232.36)] than participants
[12,793.75€ (95% CI 10393.56; 15193.93)]. As partici-
pants had significantly more inpatient days than dropouts,
they also had more sick leave days.
Health-care utilization and costs
Both CBT and SET were performed as an additional ther-
apy module to a standard 3-week inpatient rehabilitation
program. The incremental cost of adding either CBT or SET
to the costs of a standard 3-week inpatient rehabilitation
program was about €47 per patient or €282 per group.
Resource use is presented in Table 3. Patients of the
CBT at the 12-month follow-up had fewer general practi-
tioner visits, fewer inpatient days, less outpatient treatment
in hospital, fewer sick leave days and required less care-
giving from friends/relatives than patients of the SET.
Consequently, these patients at the 12-month follow-up on
average had fewer direct medical, direct non-medical and
indirect costs, but these differences where not significant
(pboot = 0.451, pboot = 0.552 and pboot = 0.396, respec-
tively; Table 4). However, the main finding considering
direct medical and indirect costs is a statistically significant
reduction in average costs after rehabilitation in both
groups. Patients incurred at baseline many more inpatient
Table 2 Baseline characteristics of patients
CBT (N = 91) SET (N = 83)
Age (mean years ± SD) 53.7 (9.6) 53.8 (10.6)
Male (%) 14.3 14.5
Employed patients (%) 52.8 42.2
Education (%)
Elementary school 34.4 39.8
Secondary school 30.0 30.1
University entrance diploma 31.1 27.7
Other 4.4 2.4
Living with a partner/relative (%) 75.6 74.1
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days and day-care days, consumed more medication and
needed more caregiving than in the 12-month follow-up.
Nevertheless, it is important to mention that the rehabili-
tation program followed a curative, invasive and generally
expensive oncological treatment: Before baseline, many
patients received either chemotherapy (63.2%) or irradia-
tion therapy (56.9%), and 93.7% were operated on. In the
12-month follow-up, only 13.9% received chemotherapy,
8.8% irradiation therapy and 17.5% were operated on.
Effectiveness data
The fear of progression mean (SD) score was at baseline
11.49 (2.45) in the CBT and 11.02 (2.41) in the SET group.
At the 12 month follow-up, the fear of progression mean
score was 10.07 (2.48) in the CBT and 9.73 (2.23) in the
SET group. Regarding the mental score of SF12, the mean
scores at baseline were 38.7 (8.9) and 37.3 (8.4), and at the
12 month follow-up 43.3 (11.4) and 42.6 (9.4) in the CBT
and SET groups, respectively.
Cost-effectiveness analysis
Both direct costs and reduction of fear of progression data
were available for 61 patients of the SET and 65 patients of
CBT. The estimated means [95% CI] of direct costs and
reduction of fear of progression were €9,045.03 [6,359.07;
12,091.87] and 1.41 [0.93; 1.92] in the SET, and €6,682.78
Table 3 Utilization of health-care resources and sick leave days during the 12-month follow-up
Indication At baseline 12-month follow-up
SET (N = 83) CBT (N = 91) SET (N = 83) CBT (N = 91)
Physician visits (per month)
General practitioner 1.17 (1.51) 1.29 (1.93) 0.98 (1.35) 0.63 (1.09)
Neurologist 0.07 (0.26) 0.06 (0.23) 0.09 (0.34) 0.05 (0.22)
Internist 0.24 (0.77) 0.44 (1.34) 0.17 (0.48) 0.32 (0.83)
Oncologist 0.69 (1.53) 0.32 (0.73) 0.31 (0.87) 0.36 (0.79)
Orthopedist 0.31 (2.21) 0.14 (0.53) 0.28 (1.10) 0.23 (0.79)
Hospital inpatient treatment (days per year) 16.21 (17.24) 13.56 (13.96) 8.87 (15.90) 3.57 (8.56)
Outpatient treatment in hospital (per month) 0.85 (1.86) 1.04 (2.21) 2.1 (12.56) 0.58 (1.59)
Day-care treatment (treatment days per year) 8.14 (14.40) 9.47 (16.16) 2.17 (5.15) 3.43 (10.34)
Psychotherapy (visits per quarter) 1.18 (3.17) 0.84 (2.33) 1.57 (4.03) 2.19 (4.64)
Physiotherapy (visits per quarter) 2.46 (5.39) 1.58 (4.95) 2.93 (7.20) 2.43 (6.19)
Massage (units per quarter) 1.84 (4.99) 0.64 (2.17) 2.68 (6.20) 1.49 (4.17)
Ergotherapy (visits per quarter) 0.07 (0.65) 0 0.07 (0.62) 0
Self-help groups (visits per month) 0.18 (0.50) 0.12 (0.39) 0.31 (0.77) 0.19 (0.55)
Relatives’ help (hours per month) 19.93 (45.43) 14.99 (35.19) 9.07 (38.17) 5.52 (10.56)
Aids and devices (absolute units per year) 19 10 12 15
Medication (costs per month) 248.63 (682.19) 229.45 (690.89) 109.69 (164.71) 105.71 (170.68)
Sick leave days (calendar days per year)a 110.50 (119.08) 111.46 (107.78) 72.82 (117.02) 50.86 (84.59)
Values (except for aids and devices) are means (standard deviations)
a Only of paid, employed patients at beginning of the study
Table 4 Mean (95%
confidence interval) costs (in the
last 12 months) at baseline and
at the 12-month follow-up
Means and confidence intervals
calculated with 1,000 bootstrap
replications. Costs are presented
in euros
Baseline 12-month follow-up p value
Direct medical costs
SET (N = 83) 13,213.16 [11,055.47; 16,012.25] 6,737.21 [5,085.96; 8,553.15] pboot = 0.000
CBT (N = 91) 13,116.39 [10,666.51; 15,707.37] 5,350.93 [4,117.45; 6,661.93] pboot = 0.000
Direct non-medical costs
SET (N = 83) 4,239.27 [2,353.15; 6,458.65] 2,039.14 [647.46; 4,197.53] pboot = 0.070
CBT (N = 91) 3,204.44 [1,785.18; 5,177.69] 1,213.87 [739.86; 1,734.75] pboot = 0.069
Indirect costs
SET (N = 44) 12,810.81 [9,362.09; 16,283.96] 6,500.68 [2,946.32; 10,691.75] pboot = 0.045
CBT (N = 55) 11,161.38 [8,535.00;13,809.28] 4,507.01 [2,482.35; 6,852.89] pboot = 0.001
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[4,998.09; 8,440.95] and 1.44 [1.02; 1.09] in the CBT.
Figure 1 shows the cost-effectiveness plane. The majority
of the cost-effect pairs after bootstrap analysis were located
in the southern quadrants of the cost-effectiveness plane,
suggesting fewer costs but very similar effects. The dif-
ferences [95% CI] in effects and direct costs amounted to
0.03 [-0.68; 0.67] and to minus €2,362.25 [-5,753.91;
622.36], respectively. Due to these figures, CBT can be
considered a dominant strategy, with the resulting ICER
[95% CI] amounting to minus €78,741.66 [-154,987.20;
110,486.32] for an additional unit of effect. Given the
acceptability curve, there is a 92.4% chance that CBT,
compared with SET, is cost-effective without a need for
additional costs to payers, i.e., there is a probability of
92.4% that the ICER is negative, meaning that CBT is less
costly, albeit similarly effective (Fig. 2).
Both direct costs and quality of life data were available
for 63 patients of the SET and 67 patients of the CBT. The
estimated means [95% CI] of all direct costs and the mental
scale of the SF-12 were €8,873.88 [6,259.44; 11,727.79]
and 43.48 [41.09; 45.81] in the SET group, as well as
€6,157.79 [4,782.19; 7,634.02] and 43.64 [40.97; 46.24] in
the CBT, resulting in a negative ICER [95% CI] amounting
to minus €16,975.56 [-20,307.00; 19,198.20] for an
additional unit of effect. The majority of the cost-effect
pairs after bootstrap analysis were located in the southern
quadrants of the cost-effectiveness plane (plane not
shown), suggesting fewer costs and very similar effects.
Given the acceptability curve (figure not shown), there is a
96.5% chance that CBT, compared with SET, is cost-
effective without the need for additional costs to payers. In
the development phase of the Fear of Progression Ques-
tionnaire, a close association between the fear of progres-
sion score and the mental score of the SF-12 was identified.
This could be one explanation for the similarity of the
results described above with results of the CEA using fear
of progression as the effect outcome [4]. Indirect costs
were not included in the cost-effectiveness analysis
because only 52.8% of CBT and 42.2% of SET participants
were still in the work force and indirect costs were calcu-
lated based on sick leave periods (Figs. 3, 4).
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Fig. 1 Incremental cost-effectiveness plane. Costs are direct costs
(medical and non-medical) within the first year after discharge.
Effects are the reduction of fear of progression within the first year
after discharge. Cost and effect pairs were estimated with 1,000
bootstrap replications
Fig. 2 Acceptability curve regarding the probability of superior cost-
effectiveness of CBT in comparison to SET. Curve estimated with
1,000 bootstrap replications
Fig. 3 Incremental cost-effectiveness plane. Costs are direct costs
(medical and non-medical) within the first year after discharge. The
effect outcome is the score of the mental scale of the SF12 within the
first year after discharge. Cost and effect pairs were estimated with
1,000 bootstrap replications
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Discussion
A recent, randomized controlled trial aiming to treat cancer
patients with elevated levels of anxiety demonstrated a
long-term reduction of fear of progression after CBT and
SET [9, 10]. From the societal perspective, whether the
improved clinical outcomes also translate into economic
benefits is of interest. Our objective was therefore to per-
form an incremental cost-effectiveness analysis of the
results of this randomized controlled trial published by
Herschbach. The incremental cost of adding either CBT or
SET to a standard 3-week inpatient rehabilitation program
was estimated to be about €282 per group. Considering
direct costs incurred in the first 6 months after discharge
from rehabilitation, we could show a superior cost-effec-
tiveness of CBT in comparison to SET without the need of
additional costs on the part of payers.
As literature shows that behavioral treatments are in
general an effective intervention for reducing unnecessary
medical usage and costs [24], we expected our patients to
report fewer costs in the follow-up. Indeed, patients
incurred at the 12-month follow-up approximately half the
average of baseline costs. However, both the CBT and the
SET were performed as an additional therapy module to a
standard 3-week inpatient rehabilitation program and fol-
lowed a curative, invasive and generally expensive onco-
logical treatment. We are therefore not able to determine to
what extent the reduction correlates with the effect of the
psychological interventions.
Patients of the CBT in follow-up statistics had fewer,
nonsignificant direct and indirect costs than patients of the
SET, mainly because of fewer inpatient and sick leave
days. Our findings are similar to those of a pilot study
targeting the impact of expressive disclosure in a prostate
cancer population, which showed a statistically nonsignifi-
cant trend toward a lower frequency of health contacts and
lower utilization of medicines in the intervention group
[11]. However, this study observed a very small sample
and the intervention is hardly comparable to ours. An RCT
evaluating a group psychosocial intervention among breast
cancer patients determined a statistically nonsignificant
between-group reduction on direct medical costs [12]. To
date, we have found no papers addressing productivity loss
among cancer populations receiving psychotherapeutical
interventions.
When interpreting our results considering the compari-
son of costs between groups, it is important to recognize
that we preferred to compare two interventions instead of
comparing CBT with no intervention at all. One conse-
quence of this approach was that it was much more difficult
to demonstrate superiority in cost-effectiveness. We also
have to keep in mind that we had many dropouts in the
follow-up and these had significantly fewer costs at base-
line than participants. A possible explanation for this is that
dropouts at baseline had more relapses and metastases than
the remaining patients. Due to their illness severity, these
patients were probably receiving palliative instead of
expensive, curative oncological treatments. Owing to the
differences described above, we made the assumption that
our costs of follow-up were probably slightly overesti-
mated due to the absence of the dropouts.
Although there was neither a statistically significant
difference in effects nor a statistically significant difference
in costs between our groups, there was a difference in the
cost-effectiveness of the interventions. Indeed, the recent
development of cost-effectiveness acceptability curves
reminds us that the absence of a statistical difference in
either costs or effects does not necessarily mean that two
treatments cannot be distinguished [25]. Moreover, because
of the usual low power of economic evaluations performed
alongside randomized clinical trials, the focus of cost-
effectiveness studies should be on estimating cost-effec-
tiveness, even when either cost or effect differences lack
conventional statistical significance [26].
Our estimated cost-effectiveness ratios are negative and
the magnitude of such ratios is not informative. Moreover,
the judgment as to whether an intervention is considered
cost-effective depends on the willingness of payers to
reimburse additional costs for additional clinical benefits.
For both reasons, we estimated an incremental cost-effec-
tiveness acceptability curve (CEAC), which represents the
probability that CBT is cost-effective, compared with SET
for a range of maximum monetary values (ceiling ratios k)
that a decision maker might be willing to pay for an addi-
tional unit of effect [27, 28]. In our study, the calculated
Fig. 4 Acceptability curve regarding the probability of superior cost-
effectiveness of CBT in comparison to SET using the mental scale of
the SF-12 as the effect outcome. Curve estimated with 1,000
bootstrap replications
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probability of 92.4% of higher cost-effectiveness without
the need of additional costs clearly states the superiority of
CBT in comparison with SET. An even higher probability is
achieved (96.5%) considering quality of life as the effect.
The comparison of these results to the literature is
limited, because the outcome assessment in psychosocial
interventions applied to cancer populations have been
heavily weighted in domains such as quality of life and
psychological distress [8]. Nevertheless, in a meta-analysis
targeting the cost-effectiveness of psychological interven-
tions for generalized anxiety disorders, CBT was the most
effective and cost-effective intervention [29]. Our results
support these findings.
Our study has some limitations. First, our economical
evaluation was performed alongside the main trial and was
probably underpowered, which led to wide confidence
limits. Second, we used a self-report questionnaire to collect
information about health-care resources, and this kind of
data source is susceptible to recall bias. Third, we extra-
polated a part of the direct cost components to obtain 1 year
figures conservatively assuming that resource use increases
constantly. Fourth, we recognize that fear of progression,
the effect used in the CEA, is an unusual outcome and
eventually difficult to interpret. However, it is an important
outcome because of its clinical relevance to patients and
clinicians. In order to increase the comparability of our
work with literature, we decided to estimate an additional
ICER using a well-recognized and easier to interpret mea-
sure: the mental scale of SF-12. Another possibility would
have been to estimate QALYs using the SF-12. However,
the accuracy of utilities estimated from the SF-12 was
recently considered unsatisfactory, especially for older and
less healthy groups, and inaccurate values can easily bias
the conclusion of a CUA [30]. Additionally, necessary
parameters of a representative sample of the German popu-
lation are not available so far. Due to the fact that the results
of a CUA would have been questionable, we decided to go
for a CEA using the SF-12 to increase the comparability of
our study with other studies.
Our main result is the superior cost-effectiveness of CBT
in comparison to SET for our sample of cancer patients with
high levels of anxiety. However, the magnitude of the
economic benefits when comparing CBT with no inter-
vention requires further investigation. Further economic
evaluations should also focus more closely on the impact of
psychological interventions on productivity loss.
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